NCT06841965

Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer

Th Efficacy and Safety of Intravenous Thrombolysis in Acute Ischemic Stroke with Cancer

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary hypothesis being tested in this trial is that ischemic stroke patients with active cancer will have improved clinical outcomes when given intravenous thrombolysis compared to standard care.

Conditions

• Stroke
• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Intravenous thrombolysis	Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).

Timeline

• Start date: 2025-03-01
• Primary completion: 2027-06-30
• Completion: 2027-12-31
• First posted: 2025-02-24
• Last updated: 2025-02-24